Eijkman Oxford Clinical Research Unit, Indonesia
Intranasal boosting regimen of Human Parainfluenza Virus Type 2-Ag85B vaccines induces superior CD4 immune response against Mycobacterium tuberculosis
BCG vaccine is the only licensed-vaccines against Mtb infections globally with vary protection rate from 0-80%. Currently, there are several TB vaccines that are on their clinical trial to surpass BCG protections. Here, we examined our potential viral vaccines of Human Parainfluenza Virus Type-2 backbone with Ag85B antigen insertion (latter called HPIV2-Ag85B) of its immunogenicity in C57BL/6 mice as TB vaccine candidate. We challenged our vaccine through several route administrations e.g.: intradermal, subcutaneous and intranasal injections in previously primed with BCG Tokyo strain six weeks mice. Vaccination performed twice with two weeks interval followed by tissues collection such as lung, lymph nodes, and spleen two weeks after last vaccination. We analysed oru HPIV2-Ag85B immune reaction by analysing its interferon gamma responses against Ag85B-pool-peptide and protein recombinant Ag85B using ELISPOT. We also compare CD4 and CD8 responses of immunized mice with ELISPOT. Our results showed intranasal administration induced highest level of IFN-γ from lung, spleen and lymph node by ELISPOT. Furthermore, twice boosting vaccination gave better IFN-γ response compare to that of single boosting vaccination. We confirmed the immune reaction induced by Ag85B antigen insertion within HPIV2 virus. Our observation also showed that HPIV2-Ag85B vaccines induced higher level of IFN-γ in CD4 cells ten-fold higher to that of CD8 cells from collected tissues. In conclusion, our HPIV2-Ag85B vaccine able to induce immunogenicity of BCG-primed cells with specific CD4 target for its immune response. We also confirmed our vaccine showed better immune response through intranasal administration and potential for intranasal vaccine candidate development against Mtb.
I had immense interest in infectious disease studies especially Tuberculosis and neglected tropical diseases. I initiate my scientific career as researcher assistant in Protein Engineering Research Group of Indonesia Institute of Science. I pursue my PhD in Biomaterial and Biomolecule Control System Group of National Institute for Material Science, Tsukuba Japan and graduated from Hokkaido University Japan. I proceed my research career as a Postdoctoral Fellow in Tsukuba Primate Research Center, National Institute for Biomedical Innovation and Health Nutrition, Tsukuba Japan. Finally, I came back to Indonesia and joined Eijkman Ofxord Clinical Research as postdoctoral fellow and performed studies mostly on molecular diagnostic of Tuberculosis and neglected tropical diseases like Leptospirosis. I am very wide open to any research collaboration.